Literature DB >> 22496331

Emerging anti-inflammatory strategies for COPD.

Mario Cazzola1, Clive P Page, Luigino Calzetta, M Gabriella Matera.   

Abstract

The hallmark of chronic obstructive pulmonary disease (COPD) is an enhanced or abnormal inflammatory immune response of the lungs to inhaled particles and gases, usually from cigarette smoke, characterised by increased numbers of neutrophils, activated macrophages and activated T-lymphocytes (Tc1 and Th1 cells). Therefore, suppression of the inflammatory response is a logical approach to the treatment of COPD. Despite the inflammatory nature of COPD, currently available anti-inflammatory therapies provide little or no benefit in COPD patients and may have detrimental effects. For this reason, there is an urgent need to discover effective and safe anti-inflammatory treatments that might prevent the relentless progression of the disease. In recent years, attention has largely been focused on inhibition of recruitment and activation of inflammatory cells, and on antagonism of their products. In this review, we put together a summary of the state-of-the-art development of clearly and/or potentially useful anti-inflammatory strategies in COPD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22496331     DOI: 10.1183/09031936.00213711

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  22 in total

1.  Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives.

Authors:  Mario Cazzola; Paola Rogliani; Maria Gabriella Matera
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

2.  Myristoylated Alanine Rich C Kinase Substrate (MARCKS) is essential to β2-integrin dependent responses of equine neutrophils.

Authors:  Mary K Sheats; Kimberly C Pescosolido; Ethan M Hefner; Eui Jae Sung; Kenneth B Adler; Samuel L Jones
Journal:  Vet Immunol Immunopathol       Date:  2014-05-02       Impact factor: 2.046

Review 3.  Innate immunity and chronic obstructive pulmonary disease: a mini-review.

Authors:  Renat Shaykhiev; Ronald G Crystal
Journal:  Gerontology       Date:  2013-09-03       Impact factor: 5.140

Review 4.  Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.

Authors:  Gerard J Criner; Jean Bourbeau; Rebecca L Diekemper; Daniel R Ouellette; Donna Goodridge; Paul Hernandez; Kristen Curren; Meyer S Balter; Mohit Bhutani; Pat G Camp; Bartolome R Celli; Gail Dechman; Mark T Dransfield; Stanley B Fiel; Marilyn G Foreman; Nicola A Hanania; Belinda K Ireland; Nathaniel Marchetti; Darcy D Marciniuk; Richard A Mularski; Joseph Ornelas; Jeremy D Road; Michael K Stickland
Journal:  Chest       Date:  2015-04       Impact factor: 9.410

5.  Maternal and perinatal obesity induce bronchial obstruction and pulmonary hypertension via IL-6-FoxO1-axis in later life.

Authors:  Jaco Selle; Katharina Dinger; Vanessa Jentgen; Daniela Zanetti; Johannes Will; Theodoros Georgomanolis; Christina Vohlen; Rebecca Wilke; Baktybek Kojonazarov; Oleksiy Klymenko; Jasmine Mohr; Silke V Koningsbruggen-Rietschel; Christopher J Rhodes; Anna Ulrich; Dharmesh Hirani; Tim Nestler; Margarete Odenthal; Esther Mahabir; Sreenath Nayakanti; Swati Dabral; Thomas Wunderlich; James Priest; Werner Seeger; Jörg Dötsch; Soni S Pullamsetti; Miguel A Alejandre Alcazar
Journal:  Nat Commun       Date:  2022-07-27       Impact factor: 17.694

Review 6.  Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease.

Authors:  Maria Gabriella Matera; Clive Page; Paola Rogliani; Luigino Calzetta; Mario Cazzola
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

7.  Cigarette smoke induction of S100A9 contributes to chronic obstructive pulmonary disease.

Authors:  Christopher Railwah; Alnardo Lora; Kanza Zahid; Hannah Goldenberg; Michael Campos; Anne Wyman; Bakr Jundi; Magdalena Ploszaj; Melissa Rivas; Abdoulaye Dabo; Susan M Majka; Robert Foronjy; Mohamed El Gazzar; Patrick Geraghty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-09-23       Impact factor: 5.464

Review 8.  The clinical use of regenerative therapy in COPD.

Authors:  Roberto Lipsi; Paola Rogliani; Luigino Calzetta; Andrea Segreti; Mario Cazzola
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-12-12

9.  T lymphocyte antigen 4-modified dendritic cell therapy for asthmatic mice guided by the CCR7 chemokine receptor.

Authors:  Yan Chen; Yongming Wang; Zhou Fu
Journal:  Int J Mol Sci       Date:  2014-08-29       Impact factor: 5.923

10.  Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects.

Authors:  Dave Singh; Leonard Siew; Jared Christensen; Jonathan Plumb; Graham W Clarke; Steve Greenaway; Christelle Perros-Huguet; Nick Clarke; Iain Kilty; Lisa Tan
Journal:  Eur J Clin Pharmacol       Date:  2015-08-13       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.